Back to News
Market Impact: 0.15
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Vaxart CEO Steve Lo highlighted the company’s oral vaccine platform at an H.C. Wainwright conference, including a government-funded COVID-19 study and development opportunities in norovirus and influenza. The presentation signals continued pipeline development but disclosed no new clinical results, financial figures, regulatory milestones, or commercial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Nasdaq futures sink 2.3% as Amazon, Intel and Alphabet send AI jitters through stocks
- Backbone of a beast – charting Nvidia's rise to networking titan
- Samsung hosts OpenAI’s Altman for talks on AI chips and infrastructure